Abstract
Background: Hepatic flares (HF), which reflect hepatitis B virus (HBV)-related immune reconstitution inflammatory syndrome (IRIS), frequently occur in patients with HBV and human immunodeficiency virus (HIV) coinfection after the start of antiretoroviral therapy (ART). The rate of hepatitis B envelope antigen (HBeAg) and hepatitis B surface antigen (HBsAg) loss is higher for patients with HF after the initiation of ART. Methods: We retrospectively examined the kinetics of the HBsAg and HBeAg levels of six HBV/HIV coinfected patients after the commencement of ART that included tenofovir. All were male and HBeAg positive. Results: Three patients developed HF after the initiation of ART. All subsequently lost HBeAg and one of them lost HBsAg after HF. None who did not experience HF lost HBeAg. The HBsAg and HBeAg levels remarkably decreased when HF occurred, but the decline of HBsAg was very slow in the periods before and after HF. The median decline of the HBsAg level at 48 weeks was 2.20LogIU/mL for patients with HF,but only 1.00LogIU/ml for patients without HF. Little decline was seen for either group in the median decline of the HBsAg level from 48 weeks to 96 weeks, 0.28LogIU/mL in the HF group and 0.06 Log IU/mL in the non-HF group. Conclusion: The immune reconstitution of a HBV/HIV coinfected patient plays an important role in the clearance of HBV. If HBsAg and HBeAg levels decrease rapidly when HF occurs, the hepatic flare would be due to HBV-related IRIS.
| Original language | English |
|---|---|
| Pages (from-to) | 264-271 |
| Number of pages | 8 |
| Journal | Journal of Infection and Chemotherapy |
| Volume | 21 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 1 2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Microbiology (medical)
- Pharmacology (medical)
- Infectious Diseases
Cite this
The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients. / Mitsumoto, Fujiko; Masayuki, Murata; Ura, Kazuya; Takayama, Koji; Hiramine, Satoshi; Shimizu, Motohiro; Toyoda, Kazuhiro; Ogawa, Eiichi; Furusyo, Norihiro; Hayashi, Jun.
In: Journal of Infection and Chemotherapy, Vol. 21, No. 4, 01.04.2015, p. 264-271.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients
AU - Mitsumoto, Fujiko
AU - Masayuki, Murata
AU - Ura, Kazuya
AU - Takayama, Koji
AU - Hiramine, Satoshi
AU - Shimizu, Motohiro
AU - Toyoda, Kazuhiro
AU - Ogawa, Eiichi
AU - Furusyo, Norihiro
AU - Hayashi, Jun
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Background: Hepatic flares (HF), which reflect hepatitis B virus (HBV)-related immune reconstitution inflammatory syndrome (IRIS), frequently occur in patients with HBV and human immunodeficiency virus (HIV) coinfection after the start of antiretoroviral therapy (ART). The rate of hepatitis B envelope antigen (HBeAg) and hepatitis B surface antigen (HBsAg) loss is higher for patients with HF after the initiation of ART. Methods: We retrospectively examined the kinetics of the HBsAg and HBeAg levels of six HBV/HIV coinfected patients after the commencement of ART that included tenofovir. All were male and HBeAg positive. Results: Three patients developed HF after the initiation of ART. All subsequently lost HBeAg and one of them lost HBsAg after HF. None who did not experience HF lost HBeAg. The HBsAg and HBeAg levels remarkably decreased when HF occurred, but the decline of HBsAg was very slow in the periods before and after HF. The median decline of the HBsAg level at 48 weeks was 2.20LogIU/mL for patients with HF,but only 1.00LogIU/ml for patients without HF. Little decline was seen for either group in the median decline of the HBsAg level from 48 weeks to 96 weeks, 0.28LogIU/mL in the HF group and 0.06 Log IU/mL in the non-HF group. Conclusion: The immune reconstitution of a HBV/HIV coinfected patient plays an important role in the clearance of HBV. If HBsAg and HBeAg levels decrease rapidly when HF occurs, the hepatic flare would be due to HBV-related IRIS.
AB - Background: Hepatic flares (HF), which reflect hepatitis B virus (HBV)-related immune reconstitution inflammatory syndrome (IRIS), frequently occur in patients with HBV and human immunodeficiency virus (HIV) coinfection after the start of antiretoroviral therapy (ART). The rate of hepatitis B envelope antigen (HBeAg) and hepatitis B surface antigen (HBsAg) loss is higher for patients with HF after the initiation of ART. Methods: We retrospectively examined the kinetics of the HBsAg and HBeAg levels of six HBV/HIV coinfected patients after the commencement of ART that included tenofovir. All were male and HBeAg positive. Results: Three patients developed HF after the initiation of ART. All subsequently lost HBeAg and one of them lost HBsAg after HF. None who did not experience HF lost HBeAg. The HBsAg and HBeAg levels remarkably decreased when HF occurred, but the decline of HBsAg was very slow in the periods before and after HF. The median decline of the HBsAg level at 48 weeks was 2.20LogIU/mL for patients with HF,but only 1.00LogIU/ml for patients without HF. Little decline was seen for either group in the median decline of the HBsAg level from 48 weeks to 96 weeks, 0.28LogIU/mL in the HF group and 0.06 Log IU/mL in the non-HF group. Conclusion: The immune reconstitution of a HBV/HIV coinfected patient plays an important role in the clearance of HBV. If HBsAg and HBeAg levels decrease rapidly when HF occurs, the hepatic flare would be due to HBV-related IRIS.
UR - http://www.scopus.com/inward/record.url?scp=84930383067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930383067&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2014.12.003
DO - 10.1016/j.jiac.2014.12.003
M3 - Article
C2 - 25596071
AN - SCOPUS:84930383067
VL - 21
SP - 264
EP - 271
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
SN - 1341-321X
IS - 4
ER -